Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies (vol 122, pg 1871, 2016)

被引：0
|
作者：
Borthakur, G. [1 ]
Popplewell, L. [1 ]
Boyiadzis, M. [1 ]
Foran, J. [1 ]
Platzbecker, U. [1 ]
Vey, N. [1 ]
Walter, R. B. [1 ]
Olin, R. [1 ]
Raza, A. [1 ]
Giagounidis, A. [1 ]
Al-Kali, A. [1 ]
Jabbour, E. [1 ]
Kadia, T. [1 ]
Garcia-Manero, G. [1 ]
Bauman, J. W. [1 ]
Wu, Y. [1 ]
Liu, Y. [1 ]
Schramek, D. [1 ]
Cox, D. S. [1 ]
Wissel, P. [1 ]
Kantarjian, H. [1 ]
机构：
[1] GlaxoSmithKline, 1250 S Collegeville Rd, Collegeville, PA 19426 USA
来源：
CANCER | 2016年 / 122卷 / 20期
关键词：
D O I：
10.1002/cncr.30178
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Please note that Yuehui Wu's correct affiliation should be listed as: GlaxoSmithKline, 1250 S. Collegeville Road, Collegeville, Pennsylvania, 19426-0989. The authors regret this error. © 2016 American Cancer Society.
引用
收藏
页码：3246 / 3246
页数：1
相关论文
共 50 条
  • [1] Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
    Borthakur, Gautam
    Popplewell, Leslie
    Boyiadzis, Michael
    Foran, James
    Platzbecker, Uwe
    Vey, Norbert
    Walter, Roland B.
    Olin, Rebecca
    Raza, Azra
    Giagounidis, Aristoteles
    Al-Kali, Aref
    Jabbour, Elias
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Bauman, John W.
    Wu, Yuehui
    Liu, Yuan
    Schramek, Dan
    Cox, Donna S.
    Wissel, Paul
    Kantarjian, Hagop
    CANCER, 2016, 122 (12) : 1871 - 1879
  • [2] Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors
    Kato, Shumei
    Porter, Robert
    Okamura, Ryosuke
    Lee, Suzanna
    Zelichov, Ori
    Tarcic, Gabi
    Vidne, Michael
    Kurzrock, Razelle
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 184 - 192
  • [3] A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
    Infante, Jeffrey R.
    Papadopoulos, Kyriakos P.
    Bendell, Johanna C.
    Patnaik, Amita
    Burris, Howard A., III
    Rasco, Drew
    Jones, Suzanne F.
    Smith, Lon
    Cox, Donna S.
    Durante, Michael
    Bellew, Kevin M.
    Park, Joohyun
    Le, Ngocdiep T.
    Tolcher, Anthony W.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) : 2077 - 2085
  • [4] PEDIATRICS CUTANEOUS REACTIONS IN PATIENT TREATED WITH THE MITOGEN-ACTIVATED PROTEIN KINASE EXTRACELLULAR SIGNAL-REGULATED KINASE INHIBITOR TRAMETINIB
    Gluck, Mirit
    Ben-Amitai, Dan
    Friedland, Rivka
    Toledano, Helen
    NEURO-ONCOLOGY, 2022, 24 : 155 - 155
  • [5] Insulin-Activated Protein Kinase Cβ Bypasses Ras and Stimulates Mitogen-Activated Protein Kinase Activity and Cell Proliferation in Muscle Cells (vol 20, pg 6327, 2000)
    Formisano, Pietro
    Oriente, Francesco
    Fiory, Francesca
    Caruso, Matilde
    Miele, Claudia
    Maitan, Maria Alessandra
    Andreozzi, Francesco
    Vigliotta, Giovanni
    Condorelli, Gerolama
    Beguinot, Francesco
    MOLECULAR AND CELLULAR BIOLOGY, 2013, 33 (07) : 1474 - 1474
  • [6] Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
    Rao, Guanhua
    Kim, In-Kyu
    Conforti, Fabio
    Liu, Jing
    Zhang, Yu-Wen
    Giaccone, Giuseppe
    EUROPEAN JOURNAL OF CANCER, 2018, 99 : 37 - 48
  • [7] The Kinase Activity-deficient Isoform of the Protein Araf Antagonizes Ras/Mitogen-activated Protein Kinase (Ras/MAPK) Signaling in the Zebrafish Embryo
    Xiong, Cong
    Liu, Xingfeng
    Meng, Anming
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (42) : 25512 - 25521
  • [8] Cutaneous Reactions in Children Treated with the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase Inhibitor Trametinib for Neural Tumors
    Boull, Christina
    Hook, Kristen
    Moertel, Christopher
    Maguiness, Sheilagh
    PEDIATRIC DERMATOLOGY, 2017, 34 (01) : 90 - 96
  • [9] Insulin-activated protein kinase Cβ bypasses Ras and stimulates mitogen-activated protein kinase activity and cell proliferation in muscle cells
    Formisano, P
    Oriente, F
    Fiory, F
    Caruso, M
    Miele, C
    Maitan, MA
    Andreozzi, F
    Vigliotta, G
    Condorelli, G
    Beguinot, F
    MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (17) : 6323 - 6333
  • [10] Clinical Outcomes among Patients with Myeloid Malignancies and Mitogen-activated Protein Kinase (MAPK) Pathway Mutations Receiving Trametinib with or without Hypomethylating Agent (HMA)
    Kurian, Tony
    Sallman, David
    Komrokji, Rami
    Lancet, Jeffrey
    Sweet, Kendra
    Talati, Chetasi
    Song, Jinming
    Hussaini, Mohammad
    Padron, Eric
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S204 - S204
12345